X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ALX 148 (evorpacept) is a highly differentiated anti-CD47 blocker with an inactive Fc effector function. It is being evaluated for the treatment of patients with untreated HPV-mediated oropharyngeal cancer.
Lead Product(s): Evorpacept,Pembrolizumab
Therapeutic Area: Oncology Product Name: ALX 148
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2024
Details:
ALX Oncology lead product candidate ALX148 (evorpacept) in combination with Rituximab and Lenalidomide is being evaluated with patients for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Lead Product(s): Evorpacept,Rituximab,Lenalidomide
Therapeutic Area: Oncology Product Name: ALX148
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2024
Details:
ALX Oncology will use the proceeds to fund ongoing development of ALX148 (evorpacept), a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain, for hematologic and solid malignancies.
Lead Product(s): Evorpacept,Trastuzumab,Ramucirumab
Therapeutic Area: Oncology Product Name: ALX148
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Piper Sandler
Deal Size: $63.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 10, 2023
Details:
ALX Oncology will use the proceeds to fund ongoing development of ALX148 (evorpacept), a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain, for hematologic and solid malignancies.
Lead Product(s): Evorpacept,Trastuzumab,Ramucirumab
Therapeutic Area: Oncology Product Name: ALX148
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Piper Sandler
Deal Size: $55.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 05, 2023
Details:
ALX Oncology will use the proceeds to fund ongoing development of ALX148 (evorpacept), a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain, for hematologic and solid malignancies.
Lead Product(s): Evorpacept,Trastuzumab,Ramucirumab
Therapeutic Area: Oncology Product Name: ALX148
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Piper Sandler
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering October 04, 2023
Details:
ALX148 (evorpacept) is a next generation CD47 blocker, which is being investigated in combination with trastuzumab in patients with HER2-positive gastric/gastroesophageal junction (“GEJ”) cancer.
Lead Product(s): Evorpacept,Trastuzumab,Ramucirumab
Therapeutic Area: Oncology Product Name: ALX148
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2023
Details:
ALX148 (evorpacept) is a fusion protein comprised of an engineered high affinity CD47 binding domain of SIRPα linked to an inactive Fc region of human immunoglobulin, being developed for the treatment of myelodysplastic syndromes.
Lead Product(s): Evorpacept,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: ALX148
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2023
Details:
ALX148 (evorpacept) is a next generation CD47 blocker, which is being investigated in patients with gastric cancer and gastroesophageal junction adenocarcinoma.
Lead Product(s): Evorpacept,Trastuzumab,Ramucirumab
Therapeutic Area: Oncology Product Name: ALX148
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2023
Details:
ALX148 (evorpacept) is a next generation CD47 blocker, which is being investigated in combination with liposomal doxorubicin and KEYTRUDA® (pembrolizumab), in patients with recurrent platinum-resistant ovarian cancer.
Lead Product(s): Evorpacept,Pembrolizumab,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: ALX148
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2023
Details:
The collaboration aims to evaluate the combination of ALX148 (evorpacept), a next generation CD47 blocker, and SARCLISA (isatuximab-irfc), Sanofi’s monoclonal antibody that targets a specific epitope on the CD38 receptor on multiple myeloma cells, for the treatment of RRMM.
Lead Product(s): Evorpacept,Isatuximab-irfc
Therapeutic Area: Oncology Product Name: ALX148
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 25, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
